» Articles » PMID: 1930331

Localization of Tumor Necrosis Factor Alpha in Synovial Tissues and at the Cartilage-pannus Junction in Patients with Rheumatoid Arthritis

Overview
Journal Arthritis Rheum
Specialty Rheumatology
Date 1991 Sep 1
PMID 1930331
Citations 172
Authors
Affiliations
Soon will be listed here.
Abstract

Using immunoaffinity-purified polyclonal anti-human recombinant tumor necrosis factor alpha (TNF alpha) F(ab')2 fragments and immunohistochemical techniques, the cells that make TNF alpha were localized in the inflamed synovial tissue of patients with rheumatoid arthritis (RA) and osteoarthritis (OA). Anti-TNF alpha antibody-stained cells were demonstrated in 9 of 11 RA and 2 of 4 OA but none of 5 normal synovial membranes examined. In RA, 26-64% of the lining layer cells were positive for TNF alpha. In the interaggregate area, 10-30% of the cells contained TNF alpha, often in a perivascular distribution, and up to 19% of the cells in lymphoid aggregates stained for TNF alpha. Some endothelial cells also stained with these antibodies. In OA tissues, the TNF alpha-containing cells were found predominantly in the deeper layer. Cells containing TNF alpha were also found at the cartilage-pannus junction in all 4 RA specimens examined. Double immunofluorescence analysis demonstrated that most TNF alpha-secreting cells in the RA synovial membrane expressed the monocyte/macrophage marker antigens CD11b and CD14, and a few expressed the T cell marker CD3. Our findings provide histologic evidence that TNF alpha is locally produced in the lining and deeper layers of the synovium by cells of the monocyte/macrophage lineage, supporting its role in inflammation. Further, our findings demonstrate that TNF alpha is produced by cells at the cartilage-pannus junction, which could affect chondrocyte metabolism, leading to the cartilage degradation in RA.

Citing Articles

Multiscale, mechanistic model of Rheumatoid Arthritis to enable decision making in late stage drug development.

Bedathuru D, Rengaswamy M, Channavazzala M, Ray T, Packrisamy P, Kumar R NPJ Syst Biol Appl. 2024; 10(1):126.

PMID: 39496637 PMC: 11535547. DOI: 10.1038/s41540-024-00454-1.


Sinomenine treats rheumatoid arthritis by inhibiting MMP9 and inflammatory cytokines expression: bioinformatics analysis and experimental validation.

Luo J, Zhu Y, Yu Y, Chen Y, He K, Liu J Sci Rep. 2024; 14(1):12786.

PMID: 38834626 PMC: 11151427. DOI: 10.1038/s41598-024-61769-x.


Effects of Modified Glucosamine on the Chondrogenic Potential of Circulating Stem Cells under Experimental Inflammation.

Gasparella M, Cenzi C, Piccione M, Madia V, Di Santo R, Tudino V Int J Mol Sci. 2023; 24(12).

PMID: 37373540 PMC: 10299282. DOI: 10.3390/ijms241210397.


Efficacy and Safety of CMAB008 Compared with Innovator Infliximab in Patients with Moderate-to-Severe Rheumatoid Arthritis Receiving Concomitant Methotrexate: A Randomized, Double-blind, Multi-center, Phase III Non-inferiority Study.

Ye H, Liu S, Xu J, Chai K, He D, Fang Y Rheumatol Ther. 2023; 10(3):757-773.

PMID: 36964872 PMC: 10140208. DOI: 10.1007/s40744-023-00544-2.


Mild inflammation persists in the glenohumeral joint of patients with shoulder instability: Cross-sectional study.

Muneshige K, Kenmoku T, Uchida K, Arendt-Nielsen L, Tazawa R, Nakawaki M Osteoarthr Cartil Open. 2022; 4(2):100241.

PMID: 36475293 PMC: 9718109. DOI: 10.1016/j.ocarto.2022.100241.